United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix labs ltd - prednisolone - gastro-resistant tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix labs ltd - prednisolone - gastro-resistant tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - diclofenac sodium - gastro-resistant tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - diclofenac sodium - gastro-resistant tablet - 50mg

European Union - English - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - evolocumab - dyslipidemias; hypercholesterolemia - lipid modifying agents - hypercholesterolaemia and mixed dyslipidaemiarepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.homozygous familial hypercholesterolaemiarepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.established atherosclerotic cardiovascular diseaserepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.for study results with respect to effects on ldl-c, cardiovascular events and populations studied see section 5.1.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - diclofenac sodium - tablets gastro-resistant - 25 milligram - acetic acid derivatives and related substances

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - diclofenac sodium - tablets gastro-resistant - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - diclofenac sodium - tablets gastro-resistant - 50 milligram - acetic acid derivatives and related substances

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

help s.a. - diclofenac (diclofenac sodium) - tablets gastro-resistant - 50mg